Abstract
Aggressive fibromatosis (also called desmoid tumor) occurs as a sporadic lesion or as part of Familial Adenomatous Polyposis, which is caused by germ line mutations in the Adenomatous polyposis Coli (APC) gene. APC is involved in the regulation of the cellular level of beta-catenin, which is a mediator in Wnt signaling. Mutational analysis of the beta-catenin and APC genes was performed in 42 sporadic aggressive fibromatoses. Nine tumors had mutations in APC, and 22 had a point mutation in beta-catenin at either codon 45 or codon 41 (producing a stabilized beta-catenin protein product). Immunohistochemistry showed an elevated beta-catenin protein level in all tumors, regardless of mutational status. Beta-catenin localized to the nucleus, and was not tyrosine phosphorylated in the six tumors in which this was tested. The demonstration of mutations in two mediators in the Wnt-APC-beta-catenin pathway implicates beta-catenin stabilization as the key factor in the pathogenesis of aggressive fibromatosis. This is the first demonstration of somatic beta-catenin mutations in a locally invasive, but non metastatic lesion composed of spindle cells, illustrating the importance of beta-catenin stabilization in a variety of cell types and neoplastic processes. Moreover, this tumor has one of the highest reported frequencies of beta-catenin mutations of any tumor type.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alman BA, Li C, Pajerski ME, Diaz-Cano S and Wolfe HJ. . 1997a Am. J. Pathol. 151: 329–334.
Alman BA, Pajerski ME, Diaz-Cano S, Corboy K and Wolfe HJ. . 1997b Diagn. Mol. Pathol. 6: 98–101.
Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, Kuhl M, Wedlich D and Birchmeier W. . 1998 Science 280: 596–599.
Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R and Birchmeier W. . 1996 Nature 382: 638–642.
Bosman FT, Goeij AFPM de and Rousch M. . 1992 J. Clin. Pathol. 45: 120–124.
Chan EF, Gat V, McNiff JM and Fuchs E. . 1999 Nat Genet 24: 410–413.
De La Costa A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A and Perret C. . 1998 Proc. Natl. Acad. Sci. USA 95: 8847–8851.
Diest PJ van, Dam P van, Henzen-Longmans SC, Berns E, Burg MEL van der, Green J and Vergote I. . 1997 J. Clin. Pathol. 50: 801–804.
Diest PJ van, Wegner AR and Lindholm J. . 1996 Analyt. Quant. Cytol. Histol. 18: 351–354.
Eccles DM, van der Luijt R, Breukel C, Bullman H, Bunyan D, Fisher A, Barber J, du Boulay C, Primrose J, Burn J and Fodde R. . 1996 Am. J. Hum. Genet. 59: 1193–1201.
Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S and Hirohashi S. . 1998 Cancer Res. 55: 3526–3528.
Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML and Rimm DL. . 1999 Cancer Res. 59: 1811–1815.
Giarola M, Wells D, Mondini P, Pilotti S, Sala P, Azzarelli A, Bertario L, Pierotti MA, Delhanty JD and Radice P. . 1998 Br. J. Cancer 78: 582–587.
Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguro S, Nakamura Y and Miyoshi Y. . 1998 Cancer Res. 58: 1021–1026.
Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P and McKechnie D. . 1991 Science 253: 661–665.
Kitaeva MN, Grogan L, Williams JP, Dimond E, Nakahara K, Hausner P, DeNobile JW, Soballe PW and Kirsch IR. . 1997 Cancer Res. 57: 4478–4481.
Koch A, Denkhaus D, Albrecht S, Leuschner I, Von Schweinitz D and Pletsch T. . 1999 Cancer Res. 59: 269–273.
Li C, Bapat B and Alman BA. . 1998 Am. J. Pathol. 153: 709–714.
Li M, Cordon-Cardo C, Gerald WL and Rosai J. . 1996 J. Hum. Pathol. 27: 939–943.
Liu D, El-Hariry I, Karayiannakis AJ, Wilding J, Chinery R, Kmiot W, McCrea PD, Gullick WJ and Pignatelli M. . 1997 Lab Invest. 77: 557–563.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW. . 1997 Science 275: 1787–1790.
Miyoshi Y, Iuao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimaro T and Nakamura Y. . 1998 Cancer Res. 58: 2524–2527.
Munemitsu S, Albert I, Souza B, Rubinfeld B and Polakis P. . 1995 Proc. Natl. Acad. Sci. USA 92: 3046–3050.
Orford K, Crockett C, Jenson JP, Weissman AM and Byers SW. . 1997 J. Biol. Chem. 272: 24735–24738.
Papkoff J, Rubinfeld B, Schryver B and Polakis P. . 1996 Mol. Cell Biol. 16: 2128–2134.
Powell SM, Peterson GM, Krush AJ, Booker S, Jen J, Giardiello FM, Hamilton SR, Vogelstein B and Kinzler KW. . 1993 New Engl. J. Med. 329: 1982–1987.
Plukker JT, van Oort I, Vermey A, Molenaar I, Hoekstra HJ, Panders AK, Dolsma WV and Koops HS. . 1995 Br. J. Surg. 82: 510–514.
Rimm DL, Caca K, Hu G, Harrison FB and Fearon ER. . 1999 Am. J. Pathol. 154: 325–339.
Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P. . 1997 Science 275: 1790–1792.
Sparks AB, Morin PJ, Vogelstein B and Kinzler KW. . 1998 Cancer Res. 58: 1130–1134.
Takayama T, Shiozaki H, Doki Y, Oka H, Inoue M, Yamamoto M, Tamura S, Shibamoto S, Ito F and Monden M. . 1998 Br. J. Cancer 77: 605–613.
Voeller HJ, Truica CI and Gelmann EP. . 1998 Cancer Res. 58: 2520–2523.
Zurawel RH, Chiappa SA, Allen C and Raffel C. . 1998 Cancer Res. 58: 896–899.
Acknowledgements
Funded by grants from the National Cancer Institute of Canada with funds from the Terry Fox Run (9129) and from the Medical Research Council of Canada (MT15136) to BA Alman. S Tejpar is funded by the Fund for Scientific Research-Flanders (FSR), F Nollet is a postdoctoral researcher with the FSR, and F van Roy is a research director with the FSR. Additional samples were contributed by: Dr Raf Sciot, Department of Pathology KUL, Dr Nils Mandahl, Department of Clinical Genetics, Lund Sweden; Dr Hubert Wolfe, Department of Pathology, New England Medical Center, Boston, MA, USA, Dr Michael Goldberg, Department of Orthopaedics, Boston, MA, USA, Dr Robert Bell, Department of Surgery, Mount Sinai Hospital, Toronto, Dr Irene Andrulis, Research Institute, Mount Sinai Hospital, Toronto and Dr William Cole, Department of Surgery, the Hospital for Sick Children, Toronto.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tejpar, S., Nollet, F., Li, C. et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 18, 6615–6620 (1999). https://doi.org/10.1038/sj.onc.1203041
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203041
Keywords
This article is cited by
-
Recurrent CTNNB1 mutations in craniofacial osteomas
Modern Pathology (2022)
-
Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review
Targeted Oncology (2022)
-
Sporadic intra-abdominal desmoid tumor with a very unusual onset: two case reports
Journal of Medical Case Reports (2021)
-
Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis – A systematic analysis of 204 cases
Scientific Reports (2020)
-
Local Control and Analgesic Efficacy of Percutaneous Cryoablation for Desmoid Tumors
CardioVascular and Interventional Radiology (2020)